首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Dahuang Fuzi Decoction Attenuates Renal Fibrosis and Ameliorates Mitochondrial Dysfunction in Chronic Aristolochic Acid Nephropathy
【2h】

Dahuang Fuzi Decoction Attenuates Renal Fibrosis and Ameliorates Mitochondrial Dysfunction in Chronic Aristolochic Acid Nephropathy

机译:大黄附子汤可减轻慢性马兜铃酸肾病的肾纤维化并改善线粒体功能障碍

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objectives. The effects of the traditional formula Dahuang Fuzi Decoction (DFD) on chronic aristolochic acid nephropathy (AAN) in mice and its underlying mechanisms were studied. Methods. Mice were randomly divided into the following six groups: the control group, the model group (AAN), the saline-treated group (AAN + vehicle), the normal dose DFD-treated group (AAN + NDFD), the high dose DFD-treated group (AAN + HDFD), and the rosiglitazone treated group (AAN + Rosi). After treating for 8 weeks, 24 h urine and blood samples were collected and the mice sacrificed to study the biochemical parameters associated with renal function. The samples were analyzed for renal fibrosis and mitochondrial dysfunction (MtD) markers. To achieve that, collagen III, collagen I, mitochondrial DNA copy numbers (mtDNA), mitochondrial membrane potential (MMP), ATP content, and ROS production were evaluated. Results. Our results showed that proteinuria, kidney function, and the renal pathological characteristics were improved by DFD and rosiglitazone. The expression of collagen III and collagen I decreased after treating with either DFD or rosiglitazone. Mitochondrial dysfunction based on the increase in ROS production, decrease in mitochondrial DNA copy numbers, and reduction of MMP and ATP content was improved by DFD and rosiglitazone. Conclusions. DFD could protect against renal impairments and ameliorate mitochondrial dysfunction in chronic AAN mice.
机译:目标。研究了大黄附子汤对小鼠慢性马兜铃酸肾病(AAN)的影响及其潜在机制。方法。将小鼠随机分为以下六组:对照组,模型组(AAN),生理盐水治疗组(AAN +载体),正常剂量DFD治疗组(AAN + NDFD),高剂量DFD-治疗组(AAN + HDFD)和罗格列酮治疗组(AAN + Rosi)。治疗8周后,收集24小时的尿液和血液样本,处死小鼠以研究与肾功能有关的生化指标。分析样品的肾纤维化和线粒体功能障碍(MtD)标记。为此,评估了胶原蛋白III,胶原蛋白I,线粒体DNA拷贝数(mtDNA),线粒体膜电位(MMP),ATP含量和ROS的产生。结果。我们的结果表明,DFD和罗格列酮改善了蛋白尿,肾功能和肾脏病理特征。用DFD或罗格列酮治疗后,III型胶原和I型胶原的表达降低。 DFD和罗格列酮可改善基于ROS产生增加,线粒体DNA拷贝数减少以及MMP和ATP含量降低的线粒体功能障碍。结论。 DFD可以预防慢性AAN小鼠的肾脏损害和减轻线粒体功能障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号